William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Oxford Saïd receives new funding for the 1+1 MBA scholarships from the Pershing Square Foundation
-
Ackman's Pershing Square Holdings down 18.6 percent so far in 2016: investor
-
Hedge funds post worst start to year since 2008: HFR
-
'No Blatant Lies' Seen from Valeant (VRX) CEO/CFO Exchange and Philidor Scripts Were Not Just Smoke and Mirrors - Evercore ISI
-
Ackman, Herbalife unscathed by probes: WSJ
-
Ackman's Pershing Square Holdings down 11.2 percent so far in 2016
-
Ackman acknowledges mistakes in 2015, details changes in portfolio
-
Portfolios With Purpose Chooses Lumentus as Social Media Agency Of Record
-
Bernstein Sees Multiple Ways to Win in Mondelez (MDLZ); End-Game Points to M&A
-
U.S. hedge funds boast lower losses as markets tumble further
-
Caution, teamwork trumped bravado for some hedge funds in 2015
-
Pershing Square's Ackman Thinks Interim Valeant (VRX) CEO Schiller Will Do 'Outstanding Job'
-
Valeant names interim CEO; timing of Pearson's return unknown
-
Valeant Pharma (VRX) Sees Sharp Upside
-
Ackman's Pershing Square ends 2015 with 20.5 pct drop
-
Jana Partners hedge fund down 5.4 percent in 2015: investor update
-
Ackman's fund sells 5 million Valeant shares to generate tax loss
-
Ackman's Pershing Square Sold Nearly 5M Shares of Valeant Pharma (VRX) for Tax Purposes
-
Market Wrap: Durable Goods Orders Outpaced in Nov.; Crude Rises on Surpise Inventory Drop; KaloBios Gets Delisting Notice
-
Ackman's Pershing Square Having an Up Month in December
-
Valeant says can contain hit to dermatology, projects 2016 growth
-
Ackman tells investors that this year could be his firm's worst ever
-
Canadian Pacific Railway (CP) CEO & CFO and Bill Ackman to Host Call on December 16
-
CP to address financial community on December 16
-
Valeant Pharma (VRX) CEO Pearson Says Walgreens Deal 'More than Replaces' Philidor
-
Valeant hires attorney, crisis management firm as U.S. scrutiny mounts
-
Norfolk Southern (NSC) said to court holders to blunt Bill Ackman's M&A push - Bloomberg
-
Ackman plays big role in laying out Canadian Pacific rail deal
-
CP says willing to take Norfolk bid to shareholders
-
CP (CP) CEO and Bill Ackman to Address Investment Community on Tuesday
-
Norfolk Southern (NSC) Board Rejects Unsolicited Offer from Canadian Pacific (CP)
-
Norfolk Southern Board Of Directors Unanimously Rejects Unsolicited Indication Of Interest From Canadian Pacific
-
Ackman's Pershing Square off 15 percent for the year: source
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Herbalife, CEO prevail in 'pyramid scheme' lawsuit
-
Pre-Open Stock Movers 11/24: (SUNE) (TASR) (BDBD) Higher; (UNXL) (CHS) (KBIO) Lower (more...)
-
After-Hours Movers 11/23: (XRX) (DY) (VRX) Higher; (BRCD) (CERE) (YY) Lower (more...)
-
Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)
-
Ackman boosts stake in drugmaker Valeant
-
Market Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.
-
Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
-
Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%
-
Hedge funds' favorite stocks lag broader market: Goldman data
-
Ackman's Pershing Square Holdings off 24.5 percent YTD
-
Pershing Square Scholarship winners announced for the Oxford 1+1 MBA
-
Norfolk Southern hostile to Canadian Pacific's $28.4 billion bid
-
Ackman discusses long Valeant Pharma (VRX), short Herbalife (HLF) at Robin Hood
-
Soros Fund Management exits its bet on Herbalife

